Table 3.
Nine analyzed technical terms with the four immunotherapy treatments combined into one technical term (‘immunotherapy agents’)
| Term (n= # of times mentioned) | Defined (% of mentioned) | Understood (% of mentioned) | |||
|---|---|---|---|---|---|
| Yes | No | Not mentioned | Yes | No | |
| Immunotherapy (n=39) | 38 (91.4) | 1 (2.6) | 0 | 19 (48.7) | 20 (51.3) |
| Immune System (n=26) | 24 (92.3) | 2 (7.7) | 13 | 23 (88.5) | 3 (11.5) |
| Immunotherapy Agents (n=26) | 26 (100) | 0 | 13 | 14 (53.8) | 12 (46.1) |
| Autoimmune (n=9) | 8 (88.9) | 1 (11.1) | 30 | 4 (44.4) | 5 (55.6) |
| Maintenance (n=6) | 1 (16.7) | 5 (83.3) | 33 | 2 (33.3) | 4 (66.7) |
| Combination Treatment (n=5) | 5 (100) | 0 | 34 | 5 (100) | 0 |
| White Blood Cells (n=4) | 4 (100) | 0 | 35 | 3 (75) | 1 (25) |
| Adjuvant Treatment (n=4) | 3 (75) | 1 (25) | 35 | 1 (25) | 3 (75) |
| Microsatellite Stability (n=3) | 3 (100) | 0 | 36 | 0 | 3 (100) |